ClinicalTrials.gg

Program

UA026

A development code.

Its studies are mostly in Psoriasis, led by Usynova Pharmaceuticals.

Furthest: phase 1, since Jun 8, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Usynova Pharmaceuticals11 open or runningphase 1since Jun 8, 2025Jun 8, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 8, 2025First study: phase 1 study in Plaque PsoriasisFirst studyNCT07038720 · 124 planned · China

TargetBeta

IL17A →read by rule
“Inhibiting IL-17A has shown remarkable clinical efficacy in psoriasis.UA026 is a high potency small molecule IL-17A inhibitor.”study text, by rule · the study

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
secukinumabruleNovartisphase 4128
ixekizumabruleEli Lillyphase 438
vunakizumabruleJiangsu HengRui Medicinephase 417
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
tibulizumabruleEli Lillyphase 25
SCT650CruleSinocelltech Groupphase 23

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07038720Plaque Psoriasis · China1RecruitingMar 1, 2026124

How it is read

Names in the registry

  • “UA026”, 1 entry

Codes read as this program: UA026.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.